Toward alpha‐synuclein seed amplification assay in clinical practice

Toward alpha‐synuclein seed amplification assay in clinical practice

Abstract INTRODUCTION Seed amplification assays (SAAs) demonstrate remarkable diagnostic performance in alpha‐synucleinopathies. However, existing protocols lack accessibility in routine laboratories, mainly due to the requirement for in‐house production of recombinant alpha‐synuclein (aSyn). This s...

Full description

Saved in:

Bibliographic Details
Main Authors:	Mathieu Verdurand, Flora Kaczorowski, Sophie Dautricourt, Virginie Desestret, Maïté Formaglio, Hélène Mollion, Gil Petitnicolas, Ali Afifi, Anthony Fourier, Antoine Garnier‐Crussard, Isabelle Quadrio
Format:	Article
Language:	English
Published:	Wiley 2025-01-01
Series:	Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring
Subjects:	alpha‐synuclein (α‐synuclein) aSyn biomarker brain homogenate (BH) cerebrospinal fluid (CSF) dementia with Lewy bodies (DLB)
Online Access:	https://doi.org/10.1002/dad2.70066
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

α-synuclein and tau: interactions, cross-seeding, and the redefinition of synucleinopathies as complex proteinopathies
by: Francisco J. Padilla-Godínez, et al.
Published: (2025-03-01)

α-Synuclein ubiquitination – functions in proteostasis and development of Lewy bodies
by: Hung-Hsiang Ho, et al.
Published: (2024-11-01)

β-synuclein in cerebrospinal fluid as a potential biomarker for distinguishing human prion diseases from Alzheimer’s and Parkinson’s disease
by: Bing Xu, et al.
Published: (2025-02-01)

Pathological α-synuclein elicits granulovacuolar degeneration independent of tau
by: Dylan J. Dues, et al.
Published: (2025-06-01)

Age-dependent progression from clearance to vulnerability in the early response of periventricular microglia to α-synuclein toxic species
by: Mª Salomé Sirerol-Piquer, et al.
Published: (2025-03-01)

Novel approaches targeting α-Synuclein for Parkinson's Disease: Current progress and future directions for the disease-modifying therapies
by: David Baggett, et al.
Published: (2024-12-01)

A fragment of Calpain-1 cleaved α-Synuclein quantified in serum is upregulated in patients with Parkinson’s disease
by: Signe Holm Nielsen, et al.
Published: (2025-04-01)

Templating of monomeric alpha-synuclein results in inflammation and SNpc dopamine neuron death in a genetic mouse model of induced synucleinopathy
by: Matthew D. Byrne, et al.
Published: (2025-07-01)

Early α-synuclein aggregation decreases corticostriatal glutamate drive and synapse density
by: Charlotte F. Brzozowski, et al.
Published: (2025-06-01)

Multivalent design of the monoclonal SynO2 antibody improves binding strength to soluble α-Synuclein aggregates
by: Inga Petersen, et al.
Published: (2023-12-01)

Lewy body dementia: exploring biomarkers and pathogenic interactions of amyloid β, tau, and α-synuclein
by: Jingfeng Liang, et al.
Published: (2025-08-01)

Lateralized ante mortem and post mortem pathology in a case of Lewy body disease with corticobasal syndrome
by: David G. Coughlin, et al.
Published: (2022-01-01)

Current strategies in the management of dementia with lewy bodies and future directions based on disease pathophysiology
by: Daniel Erskine, et al.
Published: (2025-07-01)

Erythrocytic α-Synuclein in Parkinson’s Disease and Progressive Supranuclear Palsy—A Pilot Study
by: Costanza Maria Cristiani, et al.
Published: (2024-11-01)

RETRACTED ARTICLE: Aging exacerbates the brain inflammatory micro-environment contributing to α-synuclein pathology and functional deficits in a mouse model of DLB/PD
by: Michiyo Iba, et al.
Published: (2022-09-01)

Alpha-synuclein seeding amplification assays in Lewy body dementia: a brief review
by: Maria Bregendahl, et al.
Published: (2025-07-01)

Cognitive decline profiles associated with lewy pathology in the context of Alzheimer’s disease neuropathologic change
by: Jon B. Toledo, et al.
Published: (2024-12-01)

Alpha-synuclein misfolding as fluid biomarker for Parkinson’s disease measured with the iRS platform
by: Martin Schuler, et al.
Published: (2025-04-01)

Novel CSF β-synuclein-specific assays signal early synaptic degeneration in Alzheimer’s disease
by: Sherif Bayoumy, et al.
Published: (2025-04-01)

Interactions of alpha-synuclein with membranes in Parkinson's disease: Mechanisms and therapeutic strategies
by: Baoyi Li, et al.
Published: (2024-10-01)

USP14 is crucial for proteostasis regulation and α-synuclein degradation in human SH-SY5Y dopaminergic cells
by: Vignesh Srinivasan, et al.
Published: (2025-02-01)

Human induced pluripotent stem cell-derived dopaminergic neurons release alpha-synuclein through neuronal activity
by: Maierdanjiang Nuermaimaiti, et al.
Published: (2025-03-01)

N-acetylation of α-synuclein enhances synaptic vesicle clustering mediated by α-synuclein and lysophosphatidylcholine
by: Chuchu Wang, et al.
Published: (2024-12-01)

The interplay of iron, oxidative stress, and α-synuclein in Parkinson’s disease progression
by: Yan Chen, et al.
Published: (2025-04-01)

Rektal Adenokarsinomlarda Aldehid Dehidrogenaz 1 ALDH1 ve Gamma Synuclein Ekspresyonunun Prognostik Değeri
by: Özlem Ata, et al.
Published: (2020-12-01)

Alpha-synuclein inclusions reduced by PIKfyve inhibition in Parkinson disease cell models
by: Sara Lucas-Del-Pozo, et al.
Published: (2025-10-01)

α-synuclein fibrils per se but not α-synuclein seeded aggregation causes mitochondrial dysfunction and cell death in human neurons
by: Plamena R. Angelova, et al.
Published: (2025-10-01)

A splice‐switching antisense oligonucleotide targeting APP reduces accumulation of α‐synuclein in a mouse model of Parkinson's disease
by: Rijwan U. Ahammad, et al.
Published: (2025-04-01)

Refining α-synuclein seed amplification assays to distinguish Parkinson’s disease from multiple system atrophy
by: James A. Wiseman, et al.
Published: (2025-02-01)

Synthesis and preliminary biological evaluation of a novel PET tracer for α-synuclein PET imaging
by: WANG Ce, et al.
Published: (2024-10-01)

RETRACTED ARTICLE: Hippocampal neuronal cells that accumulate α-synuclein fragments are more vulnerable to Aβ oligomer toxicity via mGluR5 – implications for dementia with Lewy bodies
by: Cassia R Overk, et al.
Published: (2014-05-01)

Autoantibody profiles in Alzheimer´s, Parkinson´s, and dementia with Lewy bodies: altered IgG affinity and IgG/IgM/IgA responses to alpha-synuclein, amyloid-beta, and tau in disease-specific pathological patterns
by: Luisa Knecht, et al.
Published: (2024-12-01)

An integrated machine learning approach delineates an entropic expansion mechanism for the binding of a small molecule to α-synuclein
by: Sneha Menon, et al.
Published: (2024-12-01)

Serum α-Synuclein in Pediatric Refractory Epilepsy: Correlation with Diagnosis and Clinical Severity
by: Aida M. S. Salem, et al.
Published: (2025-04-01)

Effect of hydrogen sulfide on alpha-synuclein aggregation and cell viability
by: Elena A. Ostrakhovitch, et al.
Published: (2025-05-01)

THE LEVEL OF Α-SYNUCLEIN IN THE PLASMA AS A BIOMARKER OF PAIN IN PARKINSON'S DISEASE TAKING INTO ACCOUNT THE MOTOR SUBTYPES
by: K.A. Tarianyk
Published: (2024-07-01)

Tet2 loss and enhanced ciliogenesis suppress α-synuclein pathology
by: Emmanuel Quansah, et al.
Published: (2025-04-01)

c-Abl Inhibitors in Parkinson’s: Exploring Hypotheses on Alpha-Synuclein Modulation
by: Jyutia Nargish, et al.
Published: (2025-04-01)

Exploring the Potential of Biomimetic Peptides in Targeting Fibrillar and Filamentous Alpha-Synuclein—An In Silico and Experimental Approach to Parkinson’s Disease
by: Sophia A. Frantzeskos, et al.
Published: (2024-11-01)

Alpha-Synuclein Dysregulation in Systemic Pathophysiology of Synucleinopathies
by: Hallie H. Dolin, et al.
Published: (2025-07-01)